Laboratory of Cellular and Molecular Pharmacology, Department of Biology, University of British Columbia Okanagan, Kelowna, BC, Canada.
Mol Cell Neurosci. 2012 Apr;49(4):430-8. doi: 10.1016/j.mcn.2012.02.006. Epub 2012 Mar 3.
Neuroinflammation, which is one of the hallmarks of neurodegenerative disorders such as Alzheimer's disease, involves secretion of pro-inflammatory mediators by activated glial cells. Secreted phospholipase A(2) group IIA (sPLA(2)IIA) has been implicated as an inflammatory mediator contributing to various peripheral inflammatory conditions; however, little is known about the role this enzyme plays in neuroinflammation. Human microglia-like promonocytic THP-1 cells and human primary astrocytes were used to study sPLA(2)IIA expression, secretion and function. Production of sPLA(2)IIA by these cells was induced in response to stimulation by pro-inflammatory mediators at both mRNA and protein levels. Removal of sPLA(2)IIA from stimulated human microglia-like cell and astrocyte supernatants by immunosorbent caused significant reduction of their toxicity towards SH-SY5Y neuroblastoma cells. Both sPLA(2)IIA specific and non-specific PLA(2) inhibitors exhibited no anti-cytotoxic or neuroprotective effects, suggesting that sPLA(2)IIA cytotoxicity is mediated by a non-enzymatic mechanism. The data obtained indicate that sPLA(2)IIA may contribute to the pathogenesis of neurodegenerative diseases involving neuroinflammation. Agents inhibiting the non-enzymatic actions of sPLA(2)IIA could be used to slow down progression of neurodegenerative processes that are driven by inflammation.
神经炎症是阿尔茨海默病等神经退行性疾病的标志之一,涉及活化的神经胶质细胞分泌促炎介质。分泌型磷脂酶 A(2)组 IIA(sPLA(2)IIA)已被认为是一种炎症介质,有助于各种外周炎症状态;然而,这种酶在神经炎症中的作用知之甚少。使用人类小胶质样前体细胞 THP-1 细胞和人原代星形胶质细胞来研究 sPLA(2)IIA 的表达、分泌和功能。这些细胞在促炎介质的刺激下,在 mRNA 和蛋白质水平上诱导 sPLA(2)IIA 的产生。用免疫吸附剂从受刺激的人类小胶质样细胞和星形胶质细胞上清液中去除 sPLA(2)IIA 会导致其对 SH-SY5Y 神经母细胞瘤细胞的毒性显著降低。sPLA(2)IIA 特异性和非特异性 PLA(2)抑制剂均未显示出抗细胞毒性或神经保护作用,表明 sPLA(2)IIA 的细胞毒性是通过非酶机制介导的。所得数据表明,sPLA(2)IIA 可能有助于涉及神经炎症的神经退行性疾病的发病机制。抑制 sPLA(2)IIA 的非酶作用的药物可用于减缓由炎症驱动的神经退行性过程的进展。